title: The catalytic histidine dyad of high density lipoprotein-associated serum paraoxonase-1 (PON1) is essential for PON1-mediated inhibition of low density lipoprotein oxidation and stimulation of macrophage cholesterol efflux.
abstract: High density lipoprotein (HDL)-associated paraoxonase-1 (PON1) anti-atherogenic properties in macrophages, i.e. inhibition of cell-mediated oxidation of low density lipoprotein (LDL) and stimulation of cholesterol efflux, were studied using recombinant variants of PON1 and apoA-I expressed in Escherichia coli and reconstituted HDL (rHDL) particles composed of phosphatidylcholine/free cholesterol (PC/FC) and apoA-I. PON1 lactonase activity is stimulated by apoA-I by approximately 7-fold relative to PC/FC particles. Wild-type (WT) PON1 bound to rHDL inhibited macrophage-mediated LDL oxidation and stimulated cholesterol efflux from the cells to 2.3- and 3.2-fold greater extents, respectively, compared with WT PON1 bound to PC/FC particles without apoA-I. We also tested PON1 catalytic histidine dyad mutants (H115Q and H134Q) that are properly folded and that bind HDL in a similar mode compared with WT PON1, but that exhibit almost no lactonase activity. These could not inhibit macrophage-mediated LDL oxidation or stimulate rHDL-mediated cholesterol efflux from the cells. Furthermore, whereas HDL-bound WT PON1 induced the formation of lysophosphatidylcholine (LPC) in macrophages, the His dyad mutants did not, suggesting that the above anti-atherogenic properties of HDL-associated PON1 involve LPC release. Indeed, enrichment of macrophages with increasing concentrations of LPC resulted in inhibition of the cells' capability to oxidize LDL and in stimulation of HDL-mediated cholesterol efflux from the macrophages in an LPC dose-dependent manner. Thus, we provide the first direct indication that the anti-atherogenic properties of PON1 are related to its lipolactonase activity and propose a model in which PON1 acts as a lipolactonase to break down oxidized lipids and to generate LPC.
authors.affiliation: Lipid Research Laboratory, Technion Faculty of Medicine, Haifa 31096, Israel.
authors.forename: Mira
authors.initials: M
authors.lastname: Rosenblat
authors.forename: Leonid
authors.initials: L
authors.lastname: Gaidukov
authors.forename: Olga
authors.initials: O
authors.lastname: Khersonsky
authors.forename: Jacob
authors.initials: J
authors.lastname: Vaya
authors.forename: Roni
authors.initials: R
authors.lastname: Oren
authors.forename: Dan S
authors.initials: DS
authors.lastname: Tawfik
authors.forename: Michael
authors.initials: M
authors.lastname: Aviram
mesh_terms: D000818:Animals; D043303:Aryldialkylphosphatase / Q000097:blood*; D001665:Binding Sites; D002384:Catalysis; D002460:Cell Line; D002474:Cell-Free System; D002784:Cholesterol / Q000378:metabolism*; D004305:Dose-Response Relationship, Drug; D004926:Escherichia coli / Q000378:metabolism; D006639:Histidine / Q000737:chemistry*; D006801:Humans; D006868:Hydrolysis; D007783:Lactones / Q000737:chemistry; D008055:Lipids / Q000737:chemistry; D008075:Lipoproteins, HDL / Q000737:chemistry; D008077:Lipoproteins, LDL / Q000737:chemistry*; D008244:Lysophosphatidylcholines / Q000737:chemistry; D008264:Macrophages / Q000378:metabolism*; D051379:Mice; D008956:Models, Chemical; D015233:Models, Statistical; D009154:Mutation; D010100:Oxygen / Q000378:metabolism*; D011485:Protein Binding; D017510:Protein Folding; D011817:Rabbits; D011994:Recombinant Proteins / Q000737:chemistry
chemical_list: D007783:Lactones; D008055:Lipids; D008075:Lipoproteins, HDL; D008077:Lipoproteins, LDL; D008244:Lysophosphatidylcholines; D011994:Recombinant Proteins; D006639:Histidine; D002784:Cholesterol; D043303:Aryldialkylphosphatase; D010100:Oxygen